Euromoney enters techie market
Euromoney, the international online information and events group, is moving into the technology sector with an eight million dollar offer to buy up Californian outfit TTI/Vanguard.
Euromoney, the international online information and events group, is moving into the technology sector with an eight million dollar offer to buy up Californian outfit TTI/Vanguard.
It is to pay $8m for an 87% stake in the US firm, with the remaining equity to be acquired in two stages of an earn-out (based on performance) by December 2014.
TTI/Vanguard offers technology executives conferences that explore how emerging and potentially disruptive innovations can affect their organisations.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Under its Institutional Investor brand, Euromoney already runs a Financial Technology Forum in the United States.
The firm said it had a strong record of running and successfully building subscription memberships in asset management in the US, Europe and Asia.
It now hopes to apply this expertise to grow TTI/Vanguard's business globally.
Richard Ensor, Chairman of Euromoney said the deal took his firm into the high-technology content sector.
"Euromoney has a successful record of acquiring events businesses and accelerating their growth globally, as demonstrated over the past 15 years by the success of Institutional Investor which now has 13 subscription memberships around the world," he said.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published
-
Will the Autumn Budget impact investment markets?
Keir Starmer has warned the Autumn Budget will be “painful”. Will it impact investment markets and should you tweak your portfolio before 30 October?
By Katie Williams Published